Introduction {#Sec1}
============

The glutamatergic hypothesis of schizophrenia suggests that dysfunction in glutamatergic signaling contributes to the pathophysiology of this disorder (Coyle et al. [@CR13]; Stahl [@CR50]). This hypothesis derives from observations of a schizophrenia-like syndrome evoked by pharmacological blockade of *N*-methyl-[d]{.smallcaps}-aspartate (NMDA) receptor channels with phencyclidine (PCP) or ketamine (Adler et al. [@CR1]; Krystal et al. [@CR33]; Lindsley et al. [@CR39]). Metabotropic glutamate receptor 5 (mGluR5) has an expression pattern mirroring that of NMDA receptors, indicating the interaction between these two receptor types (Awad et al. [@CR3]; Pisani et al. [@CR47]). Furthermore, mGluR5 is linked to the NMDA receptor via Homer, Shank, and postsynaptic density protein of 95 kDa (PSD-95; Tu et al. [@CR52]). Such linkages allow for reciprocal potentiation of function and synergistic activity between these two receptors. Indeed, many of the outcomes of mGluR5 blockade or ablation may stem from loss of the cooperative effects of mGluR5 and NMDA receptors. The disturbances in hippocampal long-term potentiation (LTP) observed in mGluR5 knockout mice are restricted to NMDA receptor-dependent pathways (Jia et al. [@CR29]; Lu et al. [@CR41]). Moreover, the mGluR5 antagonists 2-methyl-6-(phenylethynyl)pyridine (MPEP) and 3-\[(2-methyl-1,3-thiazol-4-yl)ethynyl\]-pyridine (MTEP) augment the behavioral effects induced by the NMDA receptor antagonists PCP and MK-801, including locomotor hyperactivity, prepulse inhibition (PPI) deficits, and learning impairments (Campbell et al. [@CR11]; Henry et al. [@CR22]; Homayoun et al. [@CR24]; Kinney et al. [@CR31]; Pietraszek et al. [@CR46]). In contrast, the mGluR5 agonist (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) effectively reverses these behavioral effects of ketamine (Chan et al. [@CR12]). Altogether, the data suggest that mGluR5 plays an important role in the dysregulation of NMDA-mediated neurotransmission in schizophrenia-related processes.

Sensorimotor gating, measured by PPI of the startle response, is a fundamental form of information processing that may be deficient in some schizophrenia patients and rodents treated with NMDA receptor antagonists (al-Amin and Schwarzkopf [@CR2]). Therefore, PPI is widely used to study the neurobiology of schizophrenia (Braff et al. [@CR6]; Geyer et al. [@CR18], [@CR19]). Although PPI deficits have been found in schizophrenia (Braff et al. [@CR7]), such PPI deficits are not diagnostic or unique to schizophrenia, because they are found in unaffected siblings (Wynn et al. [@CR54]), and women with schizophrenia did not differ in PPI from healthy women (Kumari et al. [@CR34]). Moreover, PPI deficits have been reported in many other nonpsychotic, psychiatric, and neurological disorders, suggesting that PPI deficits may reflect cognitive deficits in general (Geyer [@CR16]). The mGluR5 antagonist MPEP has no effect on PPI by itself but potentiates PCP-induced disruptions of PPI (Henry et al. [@CR22]). Mice lacking mGluR5 exhibit PPI deficits (Brody et al. [@CR8]; Kinney et al. [@CR31]; Lipina et al. [@CR40]) that are reversible by chronic (Gray et al. [@CR20]), but not acute (Brody et al. [@CR8]), treatment with clozapine. This reversal of PPI deficits by clozapine has been attributed to upregulation of NMDA receptors (Gray et al. [@CR20]). Moreover, a positive modulator of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors, CX546, restored PPI deficits in mGluR5 knockout mice (Lipina et al. [@CR40]). PPI deficits seen in mGluR5 knockout mice are not mimicked by acute administration of mGluR5 antagonists, and these deficits are most likely attributable to compensatory alterations in neuronal circuitry occurring during development (Kinney et al. [@CR31]). The reduced physiological responses associated with NMDA receptor function are suggested to play a critical role in the behavioral alterations seen in mGluR5 knockout mice. mGluR5 knockout mice, therefore, may represent a model of diseases characterized by PPI deficits and NMDA receptor hypofunction, such as schizophrenia. Thus, this genetic model may offer a unique opportunity to develop antipsychotic compounds with novel mechanisms of action working through the glutamatergic system.

To verify the predictive validity of this model (Geyer and Markou [@CR17]; Markou et al. [@CR43]), the effects of a variety of compounds that have been shown in earlier clinical trials of schizophrenia to modulate the glutamatergic system through distinct mechanisms and with therapeutic potential were evaluated on PPI deficits in mGluR5 knockout mice. The glutamate modulating agents included sarcosine, a glycine transporter-1 (GlyT-1) inhibitor, LY379268, an mGluR2/3 agonist, and *N*-acetylcysteine, a cysteine prodrug that indirectly activates cystine-glutamate antiporters located in the glial cells to increase glutamate levels in the extrasynaptic space. After demonstrating that sarcosine and *N*-acetylcysteine, but not the mGluR2/3 agonist LY379268, reversed PPI deficits in mGluR5 knockout mice, we examined whether the mGluR2/3 antagonist LY341495 can block the ameliorating effects of *N*-acetylcysteine on PPI deficits in mGluR5 knockout mice.

Materials and methods {#Sec2}
=====================

Animals {#Sec3}
-------

mGluR5 knockout mice (Grm5tm1Rod; Jia et al. [@CR29]) were backcrossed to C57BL/6J for at least 10 generations. Wild-type and knockout mice used in our study were generated by mating male and female heterozygous parents. Wild-type mice were littermates of the knockout animals, with the genotypes determined by polymerase chain reaction. Mice were housed in groups of four, with food and water available ad libitum. The animal holding room was maintained on a 12-h light/dark cycle (lights off at 0700 hours). All experiments were conducted in accordance with the guidelines of the American Association for the Accreditation of Laboratory Animal Care and the National Research Council\'s Guide for Care and Use of Laboratory Animals and were approved by the University of California, San Diego, Institutional Animal Care and Use Committee.

Prepulse inhibition apparatus and procedure {#Sec4}
-------------------------------------------

Three startle chambers were used to measure the startle response (SR-LAB, San Diego Instruments, San Diego, CA, USA). Each chamber consisted of a nonrestrictive Plexiglas cylinder mounted on a frame inside a lit, ventilated box (39 × 38 × 58 cm). Movements within the cylinder were detected by a piezoelectric accelerometer that was attached beneath the cylinder. Vibrations detected by the accelerometer were transduced into analog electrical signals that were subsequently digitized and stored by a computer. A total of 65 readings were recorded at 1-ms intervals, commencing at stimulus onset, and the average amplitude was used to describe the acoustic startle response. A high-frequency loudspeaker inside the box, mounted 24 cm above the chamber, generated the broadband background noise and acoustic stimuli, which were controlled by the SR-LAB software system and interface. The PPI chambers and cylinders were cleaned with 70% ethanol between mice.

The experimental session consisted of a 10-min acclimatization period in which only broadband background noise (65 dB) was presented. The acclimatization was followed by a PPI session that consisted of five different trial types: no stimulus trials (NOSTIM), a startle pulse alone trial of 40 ms at 120 dB (P120), and three prepulse + pulse trials of a 20-ms noise prepulse at 69, 73, or 77 dB, followed by a 80-ms delay, then a 40-ms 120 dB startle pulse. The NOSTIM trial consisted of only broadband background noise. All test sessions commenced and concluded with five presentations of the P120 trial, and the remainder of the session consisted of 10 presentations of each trial type in a pseudorandom order, with varying intertrial intervals (mean, 15 s; range, 12--30 s). Each animal was always tested in the same startle chamber. The startle magnitude was calculated as the average of all pulse alone trials, excluding the first and last five such trials in each session. PPI was calculated as the percent inhibition of the startle amplitude evoked by the pulse alone: $\documentclass[12pt]{minimal}
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Drugs {#Sec5}
-----

Sarcosine and *N*-acetylcysteine were purchased from Sigma (St. Louis, MO, USA) and were dissolved in saline. LY379268 and LY341495 were purchased from ANAWA (Wangen, Switzerland) and Tocris (Bristol, UK), respectively, and were dissolved in sterile water, pH adjusted to 7.4 with sodium hydroxide. All drugs were administered intraperitoneally in a volume of 10 ml/kg.

### Experimental design {#Sec6}

**Experiment 1: effect of sarcosine on PPI in wild-type and mGluR5 knockout mice** Wild-type and mGluR5 knockout mice (male, *n* = 4; female, *n* = 4) were pretreated with sarcosine (0, 100, or 300 mg/kg, i.p.) 30 min prior to the start of the PPI test in a counterbalanced order, using a within-subjects design.

**Experiment 2: effect of LY379268 on PPI in wild-type and mGluR5 knockout mice** Wild-type and mGluR5 knockout mice (male, *n* = 4; female, *n* = 3) were administered with the mGluR2/3 agonist LY379268 (0, 3, or 10 mg/kg, i.p.) 30 min prior to the start of the PPI test in a counterbalanced order, using a within-subjects design.

**Experiment 3: effect of *N*-acetylcysteine on PPI in wild-type and mGluR5 knockout mice** Wild-type and mGluR5 knockout mice (male, *n* = 5; female, *n* = 3) were pretreated with *N*-acetylcysteine (0, 50, or 100 mg/kg, i.p.) 90 min prior to the start of the PPI test in a counterbalanced order, using a within-subjects design.

**Experiment 4: combined effects of LY341495 and *N*-acetylcysteine on impaired PPI in mGluR5 knockout mice** Eight mGluR5 knockout mice (male, *n* = 4; female, *n* = 4) received drug treatment according to a within-subjects Latin-square design. mGluR5 knockout mice were pretreated with *N*-acetylcysteine (100 mg/kg, 90 min) and the mGluR2/3 antagonist LY341495 (0, 1, or 5 mg/kg, 60 min) prior to the start of the PPI test.The animals were only used for one experiment. Each test session was separated by at least 5 days.

Data analyses {#Sec7}
-------------

Multiple factor analysis of variance (ANOVA) tests were employed to assess group variations across the data. Statistically significant effects in the ANOVA were followed with Student--Newman--Keuls post hoc comparisons. The level of significance was set at 0.05. Variation with sex was tested within each dataset (as a factor in the ANOVA) before combining groups for further analysis; in no case was a significant main effect or interactive effect of sex observed. However, the limited availability of animals of each sex does not give this study statistical power to identify subtle or complex sex-related variations.

Results {#Sec8}
=======

Experiment 1: effect of sarcosine on PPI in wild-type and mGluR5 knockout mice {#Sec9}
------------------------------------------------------------------------------

Four-way repeated measures ANOVA on PPI values revealed a main effect of *sarcosine treatment* (*F*~2,42~ = 6.599, *p* \< 0.01), *genotype* (*F*~1,42~ = 35.97, *p* \< 0.001), and *prepulse intensity* (*F*~1,42~ = 82.385, *p* \< 0.001), but no main effect of *sex*. Then, the sexes were collapsed, and a three-way ANOVA was run. A significant *sarcosine treatment* × *genotype* interaction (*F*~2,42~ = 5.69, *p* \< 0.01) was shown. Post hoc tests indicated that this interaction effect was attributable to statistically lower PPI in mGluR5 knockout mice compared with wild-type mice. Furthermore, sarcosine significantly increased PPI in knockout mice, but not in wild-type mice. Specifically, statistically significant differences were observed between wild-type and knockout mice treated with vehicle, but no differences between wild-type and knockout mice treated with sarcosine at prepulse intensities of 69 and 73 dB, indicating a reversal of PPI deficits in the knockout mice. Three-way ANOVA revealed that *sarcosine treatment*, *genotype*, and *sex* had no effect on startle amplitude (Fig. [1b](#Fig1){ref-type="fig"}). Fig. 1Effects of sarcosine on PPI in mGluR5^+/+^ and mGluR^−/−^ mice. Percentage of PPI (**a**) and startle amplitude (**b**) at each of three prepulse levels (69, 73, and 77 dB) are presented. Data are expressed as mean ± SEM (*n* = 8). \* *p* \< 0.05, compared with vehicle-treated group of the same genotype; \# *p* \< 0.05, compared with the same treatment group of wild-type mice

Experiment 2: effect of LY379268 on PPI in wild-type and mGluR5 knockout mice {#Sec10}
-----------------------------------------------------------------------------

Four-way repeated-measures ANOVA on PPI values revealed a main effect of *genotype* (*F*~1,36~ = 35.66, *p* \< 0.001) and *prepulse intensity* (*F*~1,36~ = 106.52, *p* \< 0.001), indicating that the mGluR5 knockout mice exhibited a PPI deficit. There was no effect of *sex* or *LY379268 treatment*. After the sexes were collapsed and a three-way ANOVA was run, no *LY379268 treatment* × *genotype* interaction was found (Fig. [2a](#Fig2){ref-type="fig"}), and *treatment* (LY379268) and *genotype* did not affect startle amplitude (Fig. [2b](#Fig2){ref-type="fig"}). Fig. 2Effects of the mGluR2/3 agonist LY379268 on PPI in mGluR5^+/+^ and mGluR^−/−^ mice. Percentage of PPI (**a**) and startle amplitude (**b**) at each of three prepulse levels (69, 73, and 77 dB) are presented. Data are expressed as mean ± SEM (*n* = 7). \# *p* \< 0.05, compared with the same treatment group of wild-type mice

Experiment 3: effect of *N*-acetylcysteine on PPI in wild-type and mGluR5 knockout mice {#Sec11}
---------------------------------------------------------------------------------------

Four-way repeated-measures ANOVA indicated a main effect of *N-acetylcysteine treatment* (*F*~2,42~ = 6.996, *p* \< 0.01), *genotype* (*F*~1,42~ = 46.71, *p* \< 0.001), and *prepulse intensity* (*F*~2,42~ = 107.56, *p* \< 0.001), but no main effect of *sex*. After the sexes were collapsed and a three-way ANOVA was run, no *N-acetylcysteine treatment ×*  *genotype* interaction was found, which was attributable to *N*-acetylcysteine enhancing PPI in both wild-type and knockout mice at prepulse intensities of 69 and 73 dB (Fig. [3a](#Fig3){ref-type="fig"}). *Treatment* (*N*-acetylcysteine) and *genotype* did not affect startle amplitude (Fig. [3b](#Fig3){ref-type="fig"}). Fig. 3Effects of *N*-acetylcysteine on PPI in mGluR5^+/+^ and mGluR^−/−^ mice. Percentage of PPI (**a**) and startle amplitude (**b**) at each of three prepulse levels (69, 73, and 77 dB) are presented. Data are expressed as mean ± SEM (*n* = 8). \* *p* \< 0.05, compared with the vehicle-treated group of the same genotype; \# *p* \< 0.05, compared with the same treatment group of wild-type mice

Experiment 4: combined effect of LY341495 and *N*-acetylcysteine on impaired PPI in mGluR5 knockout mice {#Sec12}
--------------------------------------------------------------------------------------------------------

Three-way repeated-measures ANOVA revealed a main effect of *drug treatment* (*F*~3,42~ = 8.37, *p* \< 0.001) and *prepulse intensity* (*F*~2,42~ = 41.36, *p* \< 0.001), but no effect of *sex*. Post hoc analysis indicated that the LY341495 (1 and 5 mg/kg) plus *N*-acetylcysteine-treated groups were not different from the *N*-acetylcysteine only-treated group. This pattern of results demonstrates that the mGluR2/3 antagonist LY341495 did not block the beneficial effects *N*-acetylcysteine on PPI deficits in mGluR5 knockout mice (Fig. [4a](#Fig4){ref-type="fig"}). No significant difference was found between groups in startle amplitude (Fig. [4b](#Fig4){ref-type="fig"}). Fig. 4Effects of co-treatment of LY341495 and *N*-acetylcysteine on PPI in mGluR^−/−^ mice. Percentage of PPI (**a**) and startle amplitude (**b**) at each of three prepulse levels (69, 73, and 77 dB) are presented. Data are expressed as mean ± SEM (*n* = 8). \* *p* \< 0.05, compared with the vehicle-treated group

Discussion {#Sec13}
==========

Confirming previous findings (Brody et al. [@CR8], [@CR9]; Gray et al. [@CR20]; Kinney et al. [@CR31]; Lipina et al. [@CR40]), our results showed that mGluR5 knockout mice exhibited pronounced deficits in PPI of the startle response. Importantly, the present data showed that these PPI deficits in mGluR5 knockout mice were ameliorated by acute treatment with the GlyT-1 inhibitor sarcosine and the cysteine prodrug *N*-acetylcysteine, but not by the group II mGluR agonist LY379268. Furthermore, the reversal of PPI deficits by *N*-acetylcysteine in mGluR5 knockout mice was not blocked by the group II mGluR antagonist LY341495.

mGluR5 knockout mice are resistant to acute treatment with typical and atypical antipsychotics (Brody et al. [@CR8]). However, our results showed that acute sarcosine treatment effectively ameliorated PPI deficits in mGluR5 knockout mice, consistent with the positive results reported in antipsychotic-naive acute schizophrenia patients (Lane et al. [@CR35], [@CR36]), whereas other NMDA receptor-enhancing agents, including glycine and [d]{.smallcaps}-cycloserine, have not been effective antipsychotics (Buchanan et al. [@CR10]). Sarcosine increases the availability of the NMDA receptor co-agonist glycine via inhibition of GlyT-1, as well as directly enhances NMDA receptor function as a co-agonist (Zhang et al. [@CR56]). The dual mechanism by which sarcosine enhances NMDA receptor function might explain why sacrosine is superior to [d]{.smallcaps}-serine for the treatment of schizophrenia (Lane et al. [@CR35]). Several studies have demonstrated the ameliorating effects of GlyT-1 inhibitors on neurochemical and behavioral disturbance related to NMDA receptor hypofunction. For example, *N*\[3-(4′-flurophenyl)-3-(4′-phenylphenoxy) propyl\]sarcosine (NFPS), a more potent Gly-T1 inhibitor than sarcosine, rescues LTP (Manahan-Vaughan et al. [@CR42]) and cognitive impairment (Karasawa et al. [@CR30]) induced by administration of the NMDA receptor antagonist MK-801 in rats, prevents dopaminergic dysregulation observed after subchronic or chronic administration of the NMDA receptor antagonist PCP (Javitt et al. [@CR28]), and ameliorates cognitive deficits in mice chronically treated with PCP (Hashimoto et al. [@CR21]). Sarcosine, at the same dose as we used (100 mg/kg), has been found to effectively reduce ketamine-induced PPI deficits and c-Fos expression in certain brain regions (Yang et al. [@CR55]). Together with the observations that mGluR5 knockout mice are resistant to the disruptive effects of MK-801 on PPI and that a positive modulator of AMPA receptors restores PPI deficits in mGluR5 knockout mice (Lipina et al. [@CR40]), our findings further support a hypofunctional state of NMDA receptors in mGluR5 knockout mice which leads to behavioral abnormalities with potential relevance to schizophrenia.

Our data showed that LY379268 had no effect on PPI deficits in mGluR5 knockout mice. At the same dose levels (3 and 10 mg/kg), LY379268 significantly reduced PCP-evoked hyperactivity and behavioral alterations (i.e., circling, falling, stereotypy, and ataxia, as well as amphetamine-evoked hyperactivity; Woolley et al. [@CR53]). Additionally, LY379268 (1--3 mg/kg) reduced ketamine-evoked hyperlocomotion and ketamine-induced changes in glutamate in the dentate gyrus. However, this compound (3--12 mg/kg) did not restore PPI deficits induced by ketamine (Imre et al. [@CR27]). Similarly, other mGluR2/3 agonists, such as LY354740 or LY314582, did not ameliorate either PPI deficits induced by PCP (Henry et al. [@CR22]; Ossowska et al. [@CR44]; Schlumberger et al. [@CR48]; Schreiber et al. [@CR49]) or subchronic ketamine administration (Imre et al. [@CR26]). Although PPI cannot be considered to be a cognitive process per se, abnormalities in pre-attentive information processing may be predictive of, or lead to, complex cognitive deficits (Geyer [@CR16]). Moreover, LY354740 alone produces cognitive impairments (Higgins et al. [@CR23]). Thus, the therapeutic potential of mGluR2/3 agonists may be specific to the positive and negative symptoms, but not against sensorimotor and cognitive deficits in schizophrenia.

Clinically, *N*-acetylcysteine has been found to improve mismatch negativity, a deficit seen in schizophrenia patients (Lavoie et al. [@CR37]), and to ameliorate positive and negative symptoms as an add-on treatment (Berk et al. [@CR5]) in schizophrenia patients. Our results demonstrate that *N*-acetylcysteine significantly ameliorated the pronounced PPI deficits observed in mGluR5 knockout mice. Recently, *N*-acetylcysteine has been reported to block PCP-evoked extracellular glutamate in the prefrontal cortex and social withdrawal and memory deficits in rats, and these effects require cystine-glutamate exchange and group II mGluR activation (Baker et al. [@CR4]). Thus, the present study sought to determine whether group II mGluR activation is involved in the ameliorating effects of *N*-acetylcysteine on PPI deficits in mGluR5 knockout mice. We found that the ability of *N*-acetylcysteine to restore PPI deficits in mGluR5 knockout mice was not blocked by the mGluR2/3 antagonist LY341495. Consistent with the lack of effect of the mGluR2/3 agonist LY379268 on PPI deficits, the mechanism underlying the reversal of PPI deficits by *N*-acetylcysteine in mGluR5 knockout mice probably does not involve mGluR2/3 activation by the enhanced glutamate release induced by *N*-acetylcysteine administration. Notably, a large portion of mGluR1 is distributed extrasynaptically (Hubert and Smith [@CR25]). Moreover, recent evidence has linked activation of extrasynaptic NMDA receptors with astrocytic gliotransmission (Fellin et al. [@CR15]; Le Meur et al. [@CR38]). It is possible that extrasynaptic mGluR1 and NMDA receptors are implicated in the ameliorating effect of *N*-acetylcysteine on PPI deficits in mGluR5 knockout mice.

In addition to regulating the levels of extrasynaptic glutamate, *N*-acetylcysteine-evoked elevations of cysteine can trigger glutathione synthesis in neurons and glial cells. Glutathione is known to potentiate the NMDA receptor response to glutamate (Kohr et al. [@CR32]), either by acting at redox modulatory sites (Sullivan et al. [@CR51]) or by blocking high-affinity Zn^2+^ inhibition through Zn^2+^ chelation (Paoletti et al. [@CR45]). The attenuation of PPI deficits in mGluR5 knockout mice by *N*-acetylcysteine might be attributable to the potentiation of NMDA receptors through glutathione. Several lines of evidence suggest that oxidative stress associated with impaired metabolism of the antioxidant glutathione plays a key role in the pathophysiology of schizophrenia. Glutathione levels in cerebrospinal fluid were significantly lower in drug-free patients with schizophrenia than in control subjects (Do et al. [@CR14]). Furthermore, decreased levels of glutathione, glutathione-peroxidase, and glutathione reductase in the caudate region were observed in postmortem brain samples from patients with schizophrenia (Do et al. [@CR14]). Whether the levels of glutathione are lower in mGluR5 knockout mice compared with wild-type animals remains to be determined.

In summary, the present results indicate that lack of mGluR5 during development and in adulthood is associated with PPI deficits relevant to schizophrenia that can be improved by acute treatment with sarcosine, a GlyT-1 inhibitor and NMDA receptor co-agonist, or *N*-acetylcysteine, a precursor of glutathione and also a prodrug of cysteine, but not with the mGluR2/3 agonist LY379268. Our results, together with an earlier report showing that the AMPA receptor modulator CX546 restored PPI deficits in mGluR5 knockout mice (Lipina et al. [@CR40]), support the hypothesis that mGluR5 knockout mice represent an animal model to preclinically detect antipsychotic compounds with novel mechanisms of action that may involve potentiation of NMDA receptor function for the treatment of sensorimotor gating and cognitive impairments. Additionally, these findings provide evidence that interactions between mGluR5 and NMDA receptors, but not mGluR2/3, are involved in the regulation of PPI and suggest that positive modulation of NMDA receptor function may ameliorate the behavioral abnormalities associated with mGluR5 deficiency.
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